| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 25 | 2023 | 451 | 4.830 |
Why?
|
| Hepatitis C | 26 | 2023 | 524 | 4.660 |
Why?
|
| Veterans | 56 | 2023 | 1641 | 4.050 |
Why?
|
| Carcinoma, Hepatocellular | 42 | 2023 | 2027 | 4.010 |
Why?
|
| Barrett Esophagus | 26 | 2015 | 569 | 3.690 |
Why?
|
| Liver Neoplasms | 40 | 2023 | 4557 | 2.800 |
Why?
|
| Antiviral Agents | 21 | 2023 | 1230 | 2.670 |
Why?
|
| Liver Cirrhosis | 40 | 2023 | 941 | 2.660 |
Why?
|
| Hepacivirus | 17 | 2023 | 397 | 2.210 |
Why?
|
| HIV Infections | 26 | 2023 | 2134 | 2.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 13 | 2022 | 421 | 1.870 |
Why?
|
| United States Department of Veterans Affairs | 31 | 2023 | 605 | 1.780 |
Why?
|
| Sustained Virologic Response | 7 | 2023 | 57 | 1.710 |
Why?
|
| Benzofurans | 3 | 2022 | 38 | 1.560 |
Why?
|
| Quinoxalines | 3 | 2022 | 95 | 1.490 |
Why?
|
| Gastroesophageal Reflux | 9 | 2015 | 334 | 1.220 |
Why?
|
| United States | 76 | 2023 | 15433 | 1.140 |
Why?
|
| Hepatitis B, Chronic | 4 | 2022 | 137 | 1.140 |
Why?
|
| Imidazoles | 3 | 2022 | 999 | 1.050 |
Why?
|
| Risk Factors | 55 | 2023 | 17523 | 1.000 |
Why?
|
| International Classification of Diseases | 5 | 2024 | 83 | 0.990 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2015 | 375 | 0.960 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 38 | 0.940 |
Why?
|
| Middle Aged | 124 | 2023 | 86204 | 0.940 |
Why?
|
| Incidence | 31 | 2022 | 5673 | 0.900 |
Why?
|
| Coinfection | 7 | 2017 | 189 | 0.900 |
Why?
|
| Cohort Studies | 38 | 2022 | 9244 | 0.880 |
Why?
|
| Cryoglobulinemia | 3 | 2019 | 20 | 0.860 |
Why?
|
| Endoscopy, Digestive System | 9 | 2016 | 202 | 0.860 |
Why?
|
| Porphyria Cutanea Tarda | 2 | 2019 | 6 | 0.850 |
Why?
|
| Lichen Planus | 2 | 2019 | 22 | 0.840 |
Why?
|
| Male | 130 | 2024 | 123000 | 0.830 |
Why?
|
| Esophageal Neoplasms | 10 | 2019 | 3168 | 0.830 |
Why?
|
| Retrospective Studies | 67 | 2023 | 37905 | 0.820 |
Why?
|
| Glomerulonephritis | 2 | 2019 | 109 | 0.800 |
Why?
|
| Waist-Hip Ratio | 5 | 2015 | 59 | 0.800 |
Why?
|
| Gout | 1 | 2021 | 31 | 0.790 |
Why?
|
| Population Surveillance | 5 | 2021 | 627 | 0.780 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2020 | 363 | 0.760 |
Why?
|
| Aged | 91 | 2022 | 70117 | 0.750 |
Why?
|
| Humans | 173 | 2024 | 261506 | 0.750 |
Why?
|
| Oropharyngeal Neoplasms | 9 | 2023 | 1105 | 0.750 |
Why?
|
| Female | 118 | 2024 | 141928 | 0.710 |
Why?
|
| Acute-On-Chronic Liver Failure | 4 | 2020 | 59 | 0.640 |
Why?
|
| Adult | 74 | 2023 | 77950 | 0.640 |
Why?
|
| RNA, Viral | 4 | 2023 | 671 | 0.640 |
Why?
|
| Logistic Models | 21 | 2023 | 3441 | 0.630 |
Why?
|
| Obesity | 11 | 2022 | 2884 | 0.630 |
Why?
|
| Hepatitis B | 7 | 2021 | 258 | 0.630 |
Why?
|
| Case-Control Studies | 23 | 2021 | 6100 | 0.620 |
Why?
|
| Metformin | 1 | 2021 | 378 | 0.620 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 394 | 0.590 |
Why?
|
| Esophagus | 3 | 2015 | 553 | 0.570 |
Why?
|
| Obesity, Abdominal | 2 | 2014 | 43 | 0.560 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 108 | 0.560 |
Why?
|
| Hospitals, Veterans | 13 | 2019 | 397 | 0.560 |
Why?
|
| Tuberculin Test | 1 | 2017 | 132 | 0.550 |
Why?
|
| Odds Ratio | 14 | 2018 | 2316 | 0.550 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 82 | 0.540 |
Why?
|
| Cyclopropanes | 3 | 2022 | 88 | 0.540 |
Why?
|
| Body Mass Index | 7 | 2015 | 2203 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 1303 | 0.530 |
Why?
|
| Prevalence | 22 | 2020 | 3260 | 0.530 |
Why?
|
| Electronic Health Records | 7 | 2021 | 929 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2018 | 1538 | 0.520 |
Why?
|
| Papillomavirus Infections | 5 | 2023 | 980 | 0.520 |
Why?
|
| Comparative Effectiveness Research | 2 | 2012 | 126 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1362 | 0.510 |
Why?
|
| Bacteriuria | 3 | 2022 | 77 | 0.500 |
Why?
|
| Risk Assessment | 19 | 2023 | 6869 | 0.490 |
Why?
|
| Depression | 4 | 2020 | 1715 | 0.480 |
Why?
|
| Guideline Adherence | 4 | 2014 | 636 | 0.470 |
Why?
|
| Quality Indicators, Health Care | 6 | 2024 | 348 | 0.460 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 7789 | 0.460 |
Why?
|
| Viremia | 2 | 2011 | 177 | 0.460 |
Why?
|
| Hepatitis B virus | 4 | 2022 | 217 | 0.450 |
Why?
|
| Drug Therapy, Combination | 6 | 2023 | 2315 | 0.450 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 95 | 0.430 |
Why?
|
| Liver Diseases | 3 | 2024 | 574 | 0.430 |
Why?
|
| Adiposity | 1 | 2014 | 237 | 0.420 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 92 | 0.420 |
Why?
|
| Sarcoma, Kaposi | 3 | 2019 | 187 | 0.410 |
Why?
|
| alpha-Fetoproteins | 5 | 2014 | 237 | 0.400 |
Why?
|
| Hepatitis A Vaccines | 1 | 2010 | 10 | 0.390 |
Why?
|
| Genotype | 7 | 2023 | 4109 | 0.390 |
Why?
|
| Vomiting | 1 | 2013 | 354 | 0.390 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2008 | 58 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 787 | 0.380 |
Why?
|
| Hepatitis B Vaccines | 1 | 2010 | 51 | 0.380 |
Why?
|
| Nausea | 1 | 2013 | 525 | 0.380 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2021 | 907 | 0.370 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 4298 | 0.370 |
Why?
|
| Health Facilities | 1 | 2010 | 79 | 0.370 |
Why?
|
| Drug Prescriptions | 3 | 2012 | 289 | 0.360 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 317 | 0.360 |
Why?
|
| Inappropriate Prescribing | 3 | 2019 | 50 | 0.360 |
Why?
|
| Antimicrobial Stewardship | 2 | 2022 | 84 | 0.350 |
Why?
|
| Algorithms | 8 | 2019 | 3890 | 0.350 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 294 | 0.340 |
Why?
|
| Endoscopy | 1 | 2012 | 479 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 5437 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 585 | 0.340 |
Why?
|
| Carbamates | 2 | 2019 | 77 | 0.340 |
Why?
|
| Registries | 10 | 2019 | 2170 | 0.330 |
Why?
|
| Amides | 2 | 2019 | 123 | 0.330 |
Why?
|
| Colitis, Ulcerative | 4 | 2020 | 268 | 0.330 |
Why?
|
| Diet | 4 | 2019 | 1440 | 0.330 |
Why?
|
| Aged, 80 and over | 29 | 2021 | 29902 | 0.320 |
Why?
|
| Colon | 4 | 2021 | 670 | 0.320 |
Why?
|
| Esophagoscopy | 3 | 2015 | 291 | 0.320 |
Why?
|
| Anti-HIV Agents | 2 | 2022 | 350 | 0.320 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 526 | 0.310 |
Why?
|
| Cross-Sectional Studies | 14 | 2020 | 4314 | 0.310 |
Why?
|
| Quality Improvement | 3 | 2024 | 851 | 0.300 |
Why?
|
| Helicobacter Infections | 7 | 2015 | 1216 | 0.300 |
Why?
|
| Databases, Factual | 8 | 2020 | 2218 | 0.300 |
Why?
|
| Exercise | 1 | 2015 | 1183 | 0.300 |
Why?
|
| Referral and Consultation | 5 | 2017 | 899 | 0.290 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2008 | 220 | 0.290 |
Why?
|
| Alanine Transaminase | 5 | 2020 | 227 | 0.290 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1085 | 0.290 |
Why?
|
| HIV Protease Inhibitors | 2 | 2018 | 72 | 0.290 |
Why?
|
| Sulfonamides | 3 | 2022 | 1823 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 2403 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 148 | 0.280 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 598 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 4 | 2023 | 3976 | 0.280 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2013 | 573 | 0.270 |
Why?
|
| Anxiety | 3 | 2023 | 1179 | 0.260 |
Why?
|
| Intestinal Mucosa | 3 | 2021 | 1081 | 0.260 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.260 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 120 | 0.250 |
Why?
|
| Bacteria | 2 | 2019 | 611 | 0.250 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2016 | 85 | 0.250 |
Why?
|
| Rehabilitation Centers | 1 | 2005 | 83 | 0.250 |
Why?
|
| Liver Transplantation | 3 | 2021 | 1112 | 0.250 |
Why?
|
| Natural Language Processing | 2 | 2017 | 119 | 0.240 |
Why?
|
| Quality of Health Care | 3 | 2014 | 621 | 0.240 |
Why?
|
| Mass Screening | 5 | 2017 | 1509 | 0.240 |
Why?
|
| Sex Factors | 5 | 2019 | 2139 | 0.240 |
Why?
|
| Crohn Disease | 3 | 2020 | 351 | 0.240 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 88 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 849 | 0.240 |
Why?
|
| Ultrasonography | 5 | 2021 | 1863 | 0.240 |
Why?
|
| Texas | 10 | 2015 | 6311 | 0.230 |
Why?
|
| Age Factors | 8 | 2019 | 5377 | 0.230 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 275 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2019 | 548 | 0.230 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 4892 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 163 | 0.220 |
Why?
|
| Precancerous Conditions | 3 | 2014 | 1058 | 0.220 |
Why?
|
| HIV | 2 | 2021 | 229 | 0.220 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 14889 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2020 | 297 | 0.210 |
Why?
|
| Smoking | 6 | 2019 | 2440 | 0.210 |
Why?
|
| Tenofovir | 1 | 2022 | 23 | 0.210 |
Why?
|
| End Stage Liver Disease | 2 | 2021 | 170 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 5061 | 0.210 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 4988 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 1 | 2022 | 90 | 0.200 |
Why?
|
| Helicobacter pylori | 5 | 2019 | 1295 | 0.200 |
Why?
|
| Early Detection of Cancer | 5 | 2021 | 1258 | 0.200 |
Why?
|
| Clinical Coding | 1 | 2021 | 28 | 0.200 |
Why?
|
| Risk | 4 | 2020 | 1972 | 0.200 |
Why?
|
| Comorbidity | 4 | 2017 | 2352 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 7551 | 0.200 |
Why?
|
| Gastroenterology | 2 | 2014 | 195 | 0.190 |
Why?
|
| Albumins | 1 | 2022 | 258 | 0.190 |
Why?
|
| Consensus | 2 | 2024 | 978 | 0.190 |
Why?
|
| Veterans Health | 3 | 2017 | 181 | 0.190 |
Why?
|
| Depressive Disorder | 1 | 2005 | 557 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 4320 | 0.190 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 146 | 0.190 |
Why?
|
| Colonoscopy | 4 | 2014 | 518 | 0.190 |
Why?
|
| Proton Pump Inhibitors | 4 | 2017 | 249 | 0.190 |
Why?
|
| Adipose Tissue | 1 | 2005 | 769 | 0.180 |
Why?
|
| Young Adult | 12 | 2020 | 21445 | 0.180 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 210 | 0.180 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 860 | 0.180 |
Why?
|
| Treatment Outcome | 17 | 2022 | 32848 | 0.180 |
Why?
|
| ROC Curve | 5 | 2021 | 1183 | 0.180 |
Why?
|
| Chemoradiotherapy | 2 | 2021 | 1946 | 0.180 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 13 | 0.180 |
Why?
|
| Early Diagnosis | 2 | 2019 | 298 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 171 | 0.170 |
Why?
|
| Machine Learning | 1 | 2020 | 319 | 0.160 |
Why?
|
| Cause of Death | 2 | 2015 | 752 | 0.160 |
Why?
|
| Colorectal Neoplasms | 3 | 2011 | 3578 | 0.160 |
Why?
|
| Patient Discharge | 2 | 2019 | 661 | 0.150 |
Why?
|
| Primary Health Care | 2 | 2014 | 787 | 0.150 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 551 | 0.150 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 6 | 0.150 |
Why?
|
| Patient Admission | 1 | 2019 | 220 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 335 | 0.150 |
Why?
|
| Time Factors | 11 | 2020 | 12926 | 0.150 |
Why?
|
| Adalimumab | 1 | 2017 | 38 | 0.150 |
Why?
|
| Gastric Acid | 1 | 2017 | 42 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 164 | 0.150 |
Why?
|
| Dyslipidemias | 2 | 2020 | 235 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 411 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 50 | 0.150 |
Why?
|
| Data Mining | 1 | 2017 | 88 | 0.150 |
Why?
|
| Hospitalists | 1 | 2018 | 57 | 0.150 |
Why?
|
| Ribavirin | 2 | 2023 | 178 | 0.140 |
Why?
|
| Medicare | 2 | 2012 | 860 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2017 | 1039 | 0.140 |
Why?
|
| Infliximab | 1 | 2017 | 130 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 761 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2023 | 12873 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 228 | 0.140 |
Why?
|
| Medical Audit | 2 | 2018 | 188 | 0.140 |
Why?
|
| Hernia, Hiatal | 2 | 2013 | 63 | 0.140 |
Why?
|
| Regional Medical Programs | 1 | 2015 | 19 | 0.140 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 7 | 0.140 |
Why?
|
| Prognosis | 15 | 2020 | 21713 | 0.140 |
Why?
|
| Celiac Disease | 1 | 2016 | 75 | 0.130 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 1323 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 1454 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 235 | 0.130 |
Why?
|
| Duodenum | 1 | 2016 | 149 | 0.130 |
Why?
|
| Patient Acuity | 1 | 2015 | 72 | 0.130 |
Why?
|
| Ascites | 2 | 2016 | 198 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 73 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 461 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 4971 | 0.120 |
Why?
|
| Hospitals | 3 | 2024 | 485 | 0.120 |
Why?
|
| Program Evaluation | 2 | 2015 | 597 | 0.120 |
Why?
|
| Survival Analysis | 9 | 2017 | 9180 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 2992 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 323 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2015 | 241 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2021 | 806 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 256 | 0.120 |
Why?
|
| Glycation End Products, Advanced | 1 | 2013 | 31 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 340 | 0.120 |
Why?
|
| Infectious Disease Medicine | 1 | 2013 | 20 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2014 | 100 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 476 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 698 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 604 | 0.110 |
Why?
|
| Intuition | 1 | 2013 | 5 | 0.110 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2013 | 6 | 0.110 |
Why?
|
| Air Pollutants, Occupational | 1 | 2013 | 30 | 0.110 |
Why?
|
| Meat | 1 | 2013 | 87 | 0.110 |
Why?
|
| Adipokines | 1 | 2013 | 96 | 0.110 |
Why?
|
| Pregnancy Trimesters | 1 | 2013 | 36 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2017 | 764 | 0.110 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 21 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 918 | 0.110 |
Why?
|
| Walking | 1 | 2015 | 277 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2019 | 945 | 0.110 |
Why?
|
| Thyroid Gland | 1 | 2014 | 355 | 0.110 |
Why?
|
| Leukopenia | 1 | 2012 | 151 | 0.110 |
Why?
|
| Health Services Research | 2 | 2012 | 233 | 0.100 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2013 | 73 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 483 | 0.100 |
Why?
|
| Employment | 1 | 2013 | 129 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 739 | 0.100 |
Why?
|
| Hospitalization | 5 | 2018 | 2083 | 0.100 |
Why?
|
| Adolescent | 8 | 2023 | 31252 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2013 | 130 | 0.100 |
Why?
|
| Canada | 1 | 2013 | 429 | 0.100 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 5687 | 0.100 |
Why?
|
| Antiemetics | 1 | 2013 | 125 | 0.100 |
Why?
|
| Esophageal Diseases | 1 | 2012 | 69 | 0.100 |
Why?
|
| Serum | 1 | 2011 | 68 | 0.100 |
Why?
|
| Neoplasms | 4 | 2021 | 15193 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 198 | 0.100 |
Why?
|
| Hepatitis A Antibodies | 1 | 2010 | 6 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2013 | 262 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 690 | 0.100 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 1054 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 241 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2013 | 244 | 0.100 |
Why?
|
| Eosinophilia | 1 | 2013 | 176 | 0.100 |
Why?
|
| Probability | 3 | 2007 | 866 | 0.100 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 58 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 289 | 0.100 |
Why?
|
| Medical Records | 1 | 2012 | 415 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1945 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 6009 | 0.090 |
Why?
|
| Sleep | 1 | 2013 | 413 | 0.090 |
Why?
|
| Vegetables | 1 | 2013 | 325 | 0.090 |
Why?
|
| Folic Acid | 1 | 2013 | 349 | 0.090 |
Why?
|
| Thyroid Neoplasms | 2 | 2014 | 1866 | 0.090 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 13658 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2012 | 556 | 0.090 |
Why?
|
| Body Weight | 2 | 2022 | 1293 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2013 | 228 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 462 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 507 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 560 | 0.090 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 66 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2024 | 210 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Gastritis | 1 | 2012 | 373 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 600 | 0.080 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2008 | 20 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 46 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10035 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 67 | 0.080 |
Why?
|
| Stroke | 1 | 2017 | 1144 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 622 | 0.080 |
Why?
|
| Recurrence | 1 | 2017 | 4758 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 490 | 0.080 |
Why?
|
| Papillomaviridae | 2 | 2022 | 624 | 0.080 |
Why?
|
| Immunization Programs | 1 | 2008 | 73 | 0.080 |
Why?
|
| Liver Function Tests | 3 | 2015 | 173 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2023 | 1274 | 0.080 |
Why?
|
| Vaccination | 2 | 2010 | 1123 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 55 | 0.070 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 56 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.070 |
Why?
|
| Health Status | 2 | 2014 | 590 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2007 | 50 | 0.070 |
Why?
|
| Body Modification, Non-Therapeutic | 1 | 2006 | 2 | 0.070 |
Why?
|
| Self Report | 3 | 2017 | 756 | 0.070 |
Why?
|
| Monitoring, Ambulatory | 1 | 2006 | 63 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2278 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2013 | 756 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 1375 | 0.070 |
Why?
|
| Anthropometry | 1 | 2006 | 269 | 0.070 |
Why?
|
| Body Height | 1 | 2006 | 231 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 585 | 0.070 |
Why?
|
| SEER Program | 2 | 2020 | 1000 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 1287 | 0.060 |
Why?
|
| Demography | 2 | 2016 | 435 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2359 | 0.060 |
Why?
|
| Liver Failure | 1 | 2005 | 140 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 366 | 0.060 |
Why?
|
| Esophagitis | 1 | 2005 | 202 | 0.060 |
Why?
|
| Cytokines | 1 | 2013 | 2809 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2019 | 1546 | 0.060 |
Why?
|
| Immunogenetics | 1 | 2023 | 16 | 0.060 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 60 | 0.060 |
Why?
|
| Overweight | 1 | 2006 | 484 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2023 | 71 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 397 | 0.050 |
Why?
|
| Viral Load | 2 | 2016 | 493 | 0.050 |
Why?
|
| Biomarkers | 2 | 2011 | 5047 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1225 | 0.050 |
Why?
|
| Body Composition | 1 | 2005 | 595 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 61 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 11538 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Disease Progression | 3 | 2022 | 6682 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 524 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 402 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 545 | 0.050 |
Why?
|
| Reference Standards | 1 | 2021 | 339 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6207 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 700 | 0.040 |
Why?
|
| Pregnancy | 1 | 2013 | 7573 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 34 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2021 | 263 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 28 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2019 | 7 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 140 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 10001 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 464 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 1209 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2013 | 667 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 104 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 353 | 0.040 |
Why?
|
| Safety Management | 1 | 2019 | 132 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 254 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 259 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 343 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 305 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 770 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 4938 | 0.040 |
Why?
|
| Urine | 1 | 2018 | 143 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 1085 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 558 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 117 | 0.040 |
Why?
|
| Protective Factors | 1 | 2017 | 106 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 198 | 0.040 |
Why?
|
| Nadolol | 1 | 2016 | 38 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 1171 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1148 | 0.030 |
Why?
|
| Propranolol | 1 | 2016 | 156 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 173 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 314 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 15 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 91 | 0.030 |
Why?
|
| Simvastatin | 1 | 2015 | 106 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 33 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 1823 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 250 | 0.030 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 275 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 666 | 0.030 |
Why?
|
| Biopsy | 2 | 2012 | 3443 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 255 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 270 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 384 | 0.030 |
Why?
|
| Etidronic Acid | 1 | 2013 | 10 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 446 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2019 | 795 | 0.030 |
Why?
|
| Alendronate | 1 | 2013 | 18 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 734 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 737 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Asbestos | 1 | 2013 | 35 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 750 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 7548 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 98 | 0.030 |
Why?
|
| Azathioprine | 1 | 2012 | 66 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2013 | 75 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 490 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 285 | 0.030 |
Why?
|
| Mercaptopurine | 1 | 2012 | 130 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2013 | 123 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 150 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2013 | 170 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 409 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 353 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 295 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 980 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2012 | 684 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.020 |
Why?
|
| Lysine | 1 | 2013 | 422 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 325 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 827 | 0.020 |
Why?
|
| Kidney | 1 | 2019 | 2146 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 620 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 333 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1503 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 233 | 0.020 |
Why?
|
| Family | 1 | 2014 | 736 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2014 | 911 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 4821 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1363 | 0.020 |
Why?
|
| Calibration | 1 | 2010 | 337 | 0.020 |
Why?
|
| Methotrexate | 1 | 2012 | 999 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2014 | 620 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2012 | 613 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2009 | 119 | 0.020 |
Why?
|
| Nitroimidazoles | 1 | 2009 | 100 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 5542 | 0.020 |
Why?
|
| Amoxicillin | 1 | 2009 | 106 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2008 | 117 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 445 | 0.020 |
Why?
|
| Prejudice | 1 | 2006 | 57 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2006 | 94 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 273 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 698 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 1099 | 0.010 |
Why?
|
| Graft Survival | 1 | 2005 | 1062 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1544 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2005 | 834 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 2594 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5539 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 2803 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3230 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5767 | 0.010 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.010 |
Why?
|